Skip to main content
Top
Published in: Medical Oncology 2/2010

01-06-2010 | Original Paper

18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma

Authors: A. Azad, G. Chong, A. Tauro, A. Aly, N. C. Tebbutt

Published in: Medical Oncology | Issue 2/2010

Login to get access

Abstract

We present the case of a 65-year-old male with squamous cell carcinoma of the thoracic oesophagus on a background of neurofibromatosis type 1. On computed tomography, he was noted to have a large left-sided superior mediastinal mass. Initially, this mass was thought to be metastatic lymphadenopathy; however, it did not display fluorodeoxyglucose uptake on positron emission tomography. Subsequent biopsy confirmed the mass to be a neurofibroma and the patient commenced definitive chemo-radiation. Positron emission tomography had a major impact on management since the presumed lymph node disease was not included in the radiation field. In addition, positron emission tomography altered prognostic stratification since lymph node involvement is a poor prognostic factor in oesophageal cancer. We could only identify one other case in the English literature in which positron emission tomography was used to distinguish metastatic carcinoma from a neurofibroma, although there are a number of reports that describe the utility of positron emission tomography in differentiating benign neurofibromas from malignant connective tissue tumours.
Literature
3.
5.
go back to reference Minsky BD, et al. INT 0123 (Radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74. doi:10.1200/JCO.20.5.1167.CrossRefPubMed Minsky BD, et al. INT 0123 (Radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74. doi:10.​1200/​JCO.​20.​5.​1167.CrossRefPubMed
7.
go back to reference Ferner RE, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390–4. doi:10.1093/annonc/mdm450.CrossRefPubMed Ferner RE, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390–4. doi:10.​1093/​annonc/​mdm450.CrossRefPubMed
9.
go back to reference Ferner RE, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68(3):353–7. doi:10.1136/jnnp.68.3.353.CrossRefPubMed Ferner RE, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68(3):353–7. doi:10.​1136/​jnnp.​68.​3.​353.CrossRefPubMed
Metadata
Title
18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma
Authors
A. Azad
G. Chong
A. Tauro
A. Aly
N. C. Tebbutt
Publication date
01-06-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9196-x

Other articles of this Issue 2/2010

Medical Oncology 2/2010 Go to the issue